ViroPharma Sets Legal Argument Against FDA Decision On Generic Vancocin
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm, which markets vancomycin hydrochloride, says FDA decision on bioequivalence testing violates FOIA and other statutes.
You may also be interested in...
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.
Vancocin Generic In Vivo Testing Waiver Is Not Scientifically Sound, ViroPharma Says
More stringent testing is needed because the product treats two potentially life-threatening diseases, the firm argues in a supplement to its Petition for Stay of Action.